CB2 Tolerance Evidence Depends on Whether the Outcome Is Pain or Immune Activity
Sustained pain-response effects of a CB2 agonist do not establish that every CB2-mediated effect resists tolerance. A cannabinoid-tolerance review contrasts many favorable pain-model findings with evidence of adaptation in immune and cellular experiments.
Pain models supplied encouraging results
Piscura and colleagues summarize animal studies in which CB2 agonists retained antinociceptive activity during repeated treatment. The models included several forms of neuropathic and inflammatory pain, among other experimental conditions.
These observations support studying CB2-targeted drugs for sustained effects. They do not establish a property shared by every agonist, dosing schedule or biological response. The absence of detected tolerance also remains tied to the duration and sensitivity of the experiment.
Other measurements showed adaptation
The review describes tolerance to immunosuppressive effects of the mixed cannabinoid agonist CP55,940 as associated with CB2 activity. It also discusses CB2 desensitization and downregulation in cultured cell systems.
An immune assay, a receptor-signaling measurement and a pain-response test measure different outcomes. Results from one cannot silently be assigned to the others. CP55,940 is also a mixed agonist, so its findings should not be described as tests of a selective CB2 drug or ordinary marijuana use.
A receptor label cannot replace outcome data
The practical question is whether repeated treatment preserved the particular effect being claimed. Relevant information includes the agonist, exposure, model, comparison and observation period.
The review supports a promising but qualified account of CB2 pharmacology. It does not support the categorical claim that CB2 receptors cannot adapt, or that a cannabis product will maintain pain relief indefinitely because CB2 signaling may contribute to its effects.
Related reading: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment.
Research cited
Piscura MK and colleagues. Mechanisms of Cannabinoid Tolerance (2023). This analysis draws on the review’s discussion of the cited experiments.
